nach oben

Erschienen in:

29.09.2017 | Original Article

HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer

verfasst von: Hao Xu, Zhi-Feng Miao, Zhen-Ning Wang, Ting-Ting Zhao, Ying-Ying Xu, Yong-Xi Song, Jin-Yu Huang, Jun-Yan Zhang, Xing-Yu Liu, Jian-Hua Wu, Hui-Mian Xu

Erschienen in: Virchows Archiv | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

The current study aims to investigate the biological roles and clinical significance of HCRP1 in human gastric cancer. The expression pattern of HCRP1 in gastric cancer tissue and adjacent non-cancerous tissue was detected by immunohistochemistry. HCRP1 downregulation was found in 57 of 137 human gastric cancer samples and correlated with advanced TNM stage, positive nodal status, and relapse. Log-rank test showed that HCRP1 downregulation also correlated with poor overall survival and reduced relapse-free survival. In addition, we found that HCRP1 overexpression inhibited proliferation, colony formation, and invasion in HGC-27 cells. On the other hand, HCRP1 depletion by small interfering RNA promoted proliferation, colony formation, and invasion in SGC-7901 cells. We also treated gastric cancer cells with cisplatin. MTT and Annexin V/PI analysis were carried out to examine change of chemoresistance. We found that HCRP1 overexpression sensitized HGC-27 cells to cisplatin while its depletion reduced sensitivity in SGC-7901 cells. Moreover, we found that HCRP1 overexpression negatively regulated cyclin D1, MMP-2, p-EGFR, p-ERK, and p-AKT. HCRP1 depletion showed the opposite effects. In conclusion, our results suggest that HCRP1 downregulation might serve as an indicator for poor prognosis in gastric cancer patients. HCRP1 reduces drug resistance through regulation of EGFR-AKT signaling.

Nur mit Berechtigung zugänglich

Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R (2017) A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer 20(2):226–234. https://doi.org/10.1007/s10120-016-0603-7 CrossRefPubMed

Roberts SE, Morrison-Rees S, Samuel DG, Thorne K, Akbari A, Williams JG (2016) Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment Pharmacol Ther 43(3):334–345. https://doi.org/10.1111/apt.13474 CrossRefPubMed

Nicolas C, Sylvain M, Come L, Jean F, Anne-Marie B, Valérie J (2016) Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population. Gastric Cancer 19(2):508–514. https://doi.org/10.1007/s10120-015-0509-9 CrossRefPubMed

Fujii H, Ichikawa K, Takagaki T, Nakanishi Y, Ikegami M, Hirose S, Shimoda T (2003) Genetic evolution of alpha fetoprotein producing gastric cancer. J Clin Pathol 56(12):942–949CrossRefPubMedPubMedCentral

Polom K, Marano L, Roviello G, Petrioli R, Piagnerelli R, de Franco L, Marrelli D, Roviello F (2016) Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: from treating the incurable to preventing recurrence. Int J Hyperth 32(2):173–179. https://doi.org/10.3109/02656736.2015.1111432 CrossRef

You WC, Li JY, Blot WJ, Chang YS, Jin ML, Gail MH, Zhang L, Liu WD, Ma JL, Hu YR, Mark SD, Correa P, Fraumeni JF Jr, Xu GW (1999) Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 83(5):615–619CrossRefPubMed

Nadauld LD, Garcia S, Natsoulis G, Bell JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, Chen H, Flaherty P, Ootani A, Zhang NR, Ford JM, Kuo CJ, Ji HP (2014) Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol 15(8):428. https://doi.org/10.1186/s13059-014-0428-9 CrossRefPubMedPubMedCentral

Mendes F (1951) Problems in the diagnosis and evolution of gastric cancer. Resen Clin Cient 20(6):187–197PubMed

Bache KG, Slagsvold T, Cabezas A, Rosendal KR, Raiborg C, Stenmark H (2004) The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol Biol Cell 15(9):4337–4346. https://doi.org/10.1091/mbc.E04-03-0250 CrossRefPubMedPubMedCentral

10.

Xu J, Yang W, Wang Q, Zhang Q, Li X, Lin X, Liu X, Qin Y (2014) Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients. Int J Clin Exp Pathol 7(11):7915–7922PubMedPubMedCentral

11.

Perisanidis C, Savarese-Brenner B, Wurger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M (2013) HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. Oral Dis 19(2):206–211. https://doi.org/10.1111/j.1601-0825.2012.01972.x CrossRefPubMed

12.

Xu Z, Liang L, Wang H, Li T, Zhao M (2003) HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein. Biochem Biophys Res Commun 311(4):1057–1066CrossRefPubMed

13.

Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M (2011) hVps37A status affects prognosis and cetuximab sensitivity in ovarian cancer. Clin Cancer Res 17(4):7816–7827. https://doi.org/10.1158/1078-0432.CCR-11-0408 CrossRefPubMed

14.

Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y, Zhang Z (2017) HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition. Biomed Pharmacother 88:421–429. https://doi.org/10.1016/j.biopha.2017.01.013 CrossRefPubMed

15.

Du Y, Wang P, Sun H, Yang J, Lang X, Wang Z, Zang S, Chen L, Ma J, Sun D (2016) HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance. Tumour Biol. https://doi.org/10.1007/s13277-016-5416-0

16.

Gao X, Fan L, Li H, Li J, Liu X, Sun R, Yu Z (2016) Hepatic injury is associated with cell cycle arrest and apoptosis with alteration of cyclin A and D1 in ammonium chloride-induced hyperammonemic rats. Exp Ther Med 11(2):427–434. https://doi.org/10.3892/etm.2015.2931 CrossRefPubMed

17.

Hosooka T, Ogawa W (2016) A novel role for the cell cycle regulatory complex cyclin D1-CDK4 in gluconeogenesis. J Diabetes Investig 7(1):27–28. https://doi.org/10.1111/jdi.12369 CrossRefPubMed

18.

Kim JY, Park SY, Lyoo HR, Koo ES, Kim MS, Jeong YS (2015) Extended stability of cyclin D1 contributes to limited cell cycle arrest at G1-phase in BHK-21 cells with Japanese encephalitis virus persistent infection. J Microbiol 53(1):77–83. https://doi.org/10.1007/s12275-015-4661-z CrossRefPubMed

19.

Cheng G, Zhang L, Lv W, Dong C, Wang Y, Zhang J (2015) Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression. Med Oncol 32(1):439. https://doi.org/10.1007/s12032-014-0439-0 CrossRefPubMed

20.

Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH (2013) Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog 52(11):890–899. https://doi.org/10.1002/mc.21935 CrossRefPubMed

21.

Shimura T, Noma N, Oikawa T, Ochiai Y, Kakuda S, Kuwahara Y, Takai Y, Takahashi A, Fukumoto M (2012) Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogene 1:e12. https://doi.org/10.1038/oncsis.2012.12 CrossRef

22.

Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, Schoolfield J, Yeh IT, Troyer DA, Ghosh R (2007) Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 13(9):2784–2794. https://doi.org/10.1158/1078-0432.CCR-06-2974 CrossRefPubMedPubMedCentral

Titel: HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer
verfasst von: Hao Xu
Zhi-Feng Miao
Zhen-Ning Wang
Ting-Ting Zhao
Ying-Ying Xu
Yong-Xi Song
Jin-Yu Huang
Jun-Yan Zhang
Xing-Yu Liu
Jian-Hua Wu
Hui-Mian Xu
Publikationsdatum: 29.09.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 6/2017
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-017-2237-5

Springer Medizin

HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome

Nrf2-peroxiredoxin I axis in polymorphous adenocarcinoma is associated with low matrix metalloproteinase 2 level

Distinctive pathological and clinical features of lung carcinoids with high proliferation index

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

Synovial sarcoma showing loss of a green signal in SS18 fluorescence in situ hybridization: a clinicopathological and molecular study of 12 cases

Correlation between E-cadherin and p120 expression in invasive ductal breast cancer with a lobular component and MRI findings

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie